Search

Displaying results 4651 - 4660 of 7058 in total
  1. Drug

    Betaine

    go.drugbank.com/drugs/DB06756
    ApprovedInvestigationalNutraceutical

    It is a naturally occurring choline derivative commonly ingested through diet, with a role in regulating cellular hydration and maintaining cell function. … Betaine is a methyl group donor that functions in the normal metabolic cycle of methionine.

    Mixtures: Face It Hd Perfect Bb Spf30 Pa 02, Face It Hd Perfect Bb Spf30 Pa 01
  2. Drug

    Samidorphan

    go.drugbank.com/drugs/DB12543
    ApprovedInvestigational

    , and a longer half-life, making it an attractive candidate for oral dosing. … [A235638, A235643] Samidorphan is a novel opioid antagonist structurally related to [naltrexone], with a higher affinity for opioid receptors, more potent μ-opioid receptor antagonism, higher oral bioavailability

  3. Drug

    Crinecerfont

    go.drugbank.com/drugs/DB18518
    ApprovedInvestigational

    [A264818] Crinecerfont was approved by the FDA in December 2024 as an adjunct to glucocorticoid replacement in patients with CAH.[L51973,L51993] … [A264818] Crinecerfont is a selective antagonist of corticotropin-releasing factor (CRF) type 1 receptor that works to reduce excessive ACTH secretion from the pituitary.

  4. Drug

    Daraxonrasib

    go.drugbank.com/drugs/DB22308
    ApprovedInvestigational

    RAS variants rather than a single mutation. … [L64039,L64041] Because it targets a broad range of RAS genotypes, it treats tumors with or without an identified RAS mutation and does not require a companion diagnostic test.

  5. Drug

    Omaveloxolone

    go.drugbank.com/drugs/DB12513
    ApprovedInvestigational

    Omaveloxolone (RTA-408) is a semisynthetic oleanane triterpenoid with antioxidant and anti-inflammatory properties. … Therefore, the use of Nrf2 activators such as omaveloxolone represents a therapeutic advantage in this group of patients.

  6. Drug

    Pafolacianine

    go.drugbank.com/drugs/DB15413
    ApprovedInvestigational

    Pafolacianine, or OTL38, is a folate analogue conjugated with a fluorescent dye that absorbs light in the near-infrared (NIR) spectrum [A242572] within a range of 760 nm to 785 nm, with a peak absorption … It emits fluorescence within a range of 790 nm to 815 nm with a peak emission of 796 nm.

    Categories: Compounds used in a research, industrial, or household setting
  7. Drug

    Lorcaserin

    go.drugbank.com/drugs/DB04871
    ApprovedInvestigationalWithdrawn

    This decision was based on the results of a clinical trial assessing the risk of heart-related problems that found that patients treated with lorcaserin may have a higher risk of cancer. … In February 2020, the FDA issued a Drug Safety Communication requesting the manufacturer of Belviq (lorcaserin hydrochloride tablets, 10 mg) and Belviq XR (lorcaserin hydrochloride extended-release tablets

  8. Drug

    Melarsomine

    go.drugbank.com/drugs/DB11528
    ExperimentalVet approved

    Melarsomine is a trypanocidal agent marketed by Merial under the trade name Immiticide. … It is the only FDA-approved treatment for adult heartworm infection in dogs, however, is is not approved for use in dogs with late-stage infection.

  9. Drug

    Elivaldogene autotemcel

    go.drugbank.com/drugs/DB16746
    Approved

    [L40298] In September 2022, Skysona was approved by the FDA.[L43247] … Elivaldogene autotemcel is a gene therapy consisting of genetically modified autologous cells.

    International brands: Lenti-D
  10. Drug

    Cloxazolam

    go.drugbank.com/drugs/DB01553
    Experimental

    The usual dose of cloxazolam in adults is 3-12mg/day for anti-anxiety. … Cloxazolam is a benzodiazepine with anxiolytic, sedative/hypnotic, muscle relaxant, and antiepileptic effects.